 | • レポートコード：MRC2312MG13271 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥455,000 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥682,500 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の細胞&遺伝子治療CDMO市場規模と予測を収録しています。・世界の細胞&遺伝子治療CDMO市場：売上、2018年-2023年、2024年-2029年 ・世界の細胞&遺伝子治療CDMO市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の細胞&遺伝子治療CDMO市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「治験材料用CDMO」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 細胞&遺伝子治療CDMOのグローバル主要企業は、Lonza、 Charles River Laboratories、 Cytiva、 Catalent Biologics、 FUJIFILM Diosynth Biotechnologies、 BioCentriq、 RoslinCT、 Thermo Scientific、 Mesoblast、 Cellularity、 Bluebird Bio、 Editas Medicine、 Andelyn Biosciences、 Wuxi Advanced Therapies、 AGC Biologics、 Pfizer CentreOne、 Almac Group、 PCI Pharma Servicesなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、細胞&遺伝子治療CDMOのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の細胞&遺伝子治療CDMO市場：タイプ別、2018年-2023年、2024年-2029年 世界の細胞&遺伝子治療CDMO市場：タイプ別市場シェア、2022年 ・治験材料用CDMO、開発&製造用CDMO、その他 世界の細胞&遺伝子治療CDMO市場：用途別、2018年-2023年、2024年-2029年 世界の細胞&遺伝子治療CDMO市場：用途別市場シェア、2022年 ・製薬会社、バイオテクノロジー会社、その他 世界の細胞&遺伝子治療CDMO市場：地域・国別、2018年-2023年、2024年-2029年 世界の細胞&遺伝子治療CDMO市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における細胞&遺伝子治療CDMOのグローバル売上、2018年-2023年 ・主要企業における細胞&遺伝子治療CDMOのグローバル売上シェア、2022年 ・主要企業における細胞&遺伝子治療CDMOのグローバル販売量、2018年-2023年 ・主要企業における細胞&遺伝子治療CDMOのグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Lonza、 Charles River Laboratories、 Cytiva、 Catalent Biologics、 FUJIFILM Diosynth Biotechnologies、 BioCentriq、 RoslinCT、 Thermo Scientific、 Mesoblast、 Cellularity、 Bluebird Bio、 Editas Medicine、 Andelyn Biosciences、 Wuxi Advanced Therapies、 AGC Biologics、 Pfizer CentreOne、 Almac Group、 PCI Pharma Services ************************************************************* ・調査・分析レポートの概要 細胞&遺伝子治療CDMO市場の定義 市場セグメント 世界の細胞&遺伝子治療CDMO市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の細胞&遺伝子治療CDMO市場規模 世界の細胞&遺伝子治療CDMO市場規模：2022年 VS 2029年 世界の細胞&遺伝子治療CDMO市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの細胞&遺伝子治療CDMOの売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の細胞&遺伝子治療CDMO製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：治験材料用CDMO、開発&製造用CDMO、その他 細胞&遺伝子治療CDMOのタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：製薬会社、バイオテクノロジー会社、その他 細胞&遺伝子治療CDMOの用途別グローバル売上・予測 ・地域別市場分析 地域別細胞&遺伝子治療CDMO市場規模 2022年と2029年 地域別細胞&遺伝子治療CDMO売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Lonza、 Charles River Laboratories、 Cytiva、 Catalent Biologics、 FUJIFILM Diosynth Biotechnologies、 BioCentriq、 RoslinCT、 Thermo Scientific、 Mesoblast、 Cellularity、 Bluebird Bio、 Editas Medicine、 Andelyn Biosciences、 Wuxi Advanced Therapies、 AGC Biologics、 Pfizer CentreOne、 Almac Group、 PCI Pharma Services ... |
This research report provides a comprehensive analysis of the Cell and Gene Therapy CDMO market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Cell and Gene Therapy CDMO market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Cell and Gene Therapy CDMO, challenges faced by the industry, and potential opportunities for market players.
The global Cell and Gene Therapy CDMO market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Cell and Gene Therapy CDMO market presents opportunities for various stakeholders, including Pharmaceutical Company, Biotechnology Company. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Cell and Gene Therapy CDMO market. Additionally, the growing consumer demand present avenues for market expansion.
The global Cell and Gene Therapy CDMO market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
Key Features:
The research report on the Cell and Gene Therapy CDMO market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Cell and Gene Therapy CDMO market.
Market Overview: The report provides a comprehensive overview of the Cell and Gene Therapy CDMO market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Clinical Trial Material CDMOs, Development and Manufacturing CDMOs), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Cell and Gene Therapy CDMO market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Cell and Gene Therapy CDMO market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Cell and Gene Therapy CDMO market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Cell and Gene Therapy CDMO market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Cell and Gene Therapy CDMO market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Cell and Gene Therapy CDMO market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Cell and Gene Therapy CDMO, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Cell and Gene Therapy CDMO market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Cell and Gene Therapy CDMO market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Clinical Trial Material CDMOs
Development and Manufacturing CDMOs
Other
Market segment by Application
Pharmaceutical Company
Biotechnology Company
Other
Global Cell and Gene Therapy CDMO Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Lonza
Charles River Laboratories
Cytiva
Catalent Biologics
FUJIFILM Diosynth Biotechnologies
BioCentriq
RoslinCT
Thermo Scientific
Mesoblast
Cellularity
Bluebird Bio
Editas Medicine
Andelyn Biosciences
Wuxi Advanced Therapies
AGC Biologics
Pfizer CentreOne
Almac Group
PCI Pharma Services
Outline of Major Chapters:
Chapter 1: Introduces the definition of Cell and Gene Therapy CDMO, market overview.
Chapter 2: Global Cell and Gene Therapy CDMO market size in revenue.
Chapter 3: Detailed analysis of Cell and Gene Therapy CDMO company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Cell and Gene Therapy CDMO in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Cell and Gene Therapy CDMO Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Cell and Gene Therapy CDMO Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Cell and Gene Therapy CDMO Overall Market Size
2.1 Global Cell and Gene Therapy CDMO Market Size: 2022 VS 2029
2.2 Global Cell and Gene Therapy CDMO Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Cell and Gene Therapy CDMO Players in Global Market
3.2 Top Global Cell and Gene Therapy CDMO Companies Ranked by Revenue
3.3 Global Cell and Gene Therapy CDMO Revenue by Companies
3.4 Top 3 and Top 5 Cell and Gene Therapy CDMO Companies in Global Market, by Revenue in 2022
3.5 Global Companies Cell and Gene Therapy CDMO Product Type
3.6 Tier 1, Tier 2 and Tier 3 Cell and Gene Therapy CDMO Players in Global Market
3.6.1 List of Global Tier 1 Cell and Gene Therapy CDMO Companies
3.6.2 List of Global Tier 2 and Tier 3 Cell and Gene Therapy CDMO Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Cell and Gene Therapy CDMO Market Size Markets, 2022 & 2029
4.1.2 Clinical Trial Material CDMOs
4.1.3 Development and Manufacturing CDMOs
4.1.4 Other
4.2 By Type – Global Cell and Gene Therapy CDMO Revenue & Forecasts
4.2.1 By Type – Global Cell and Gene Therapy CDMO Revenue, 2018-2023
4.2.2 By Type – Global Cell and Gene Therapy CDMO Revenue, 2024-2029
4.2.3 By Type – Global Cell and Gene Therapy CDMO Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Cell and Gene Therapy CDMO Market Size, 2022 & 2029
5.1.2 Pharmaceutical Company
5.1.3 Biotechnology Company
5.1.4 Other
5.2 By Application – Global Cell and Gene Therapy CDMO Revenue & Forecasts
5.2.1 By Application – Global Cell and Gene Therapy CDMO Revenue, 2018-2023
5.2.2 By Application – Global Cell and Gene Therapy CDMO Revenue, 2024-2029
5.2.3 By Application – Global Cell and Gene Therapy CDMO Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Cell and Gene Therapy CDMO Market Size, 2022 & 2029
6.2 By Region – Global Cell and Gene Therapy CDMO Revenue & Forecasts
6.2.1 By Region – Global Cell and Gene Therapy CDMO Revenue, 2018-2023
6.2.2 By Region – Global Cell and Gene Therapy CDMO Revenue, 2024-2029
6.2.3 By Region – Global Cell and Gene Therapy CDMO Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Cell and Gene Therapy CDMO Revenue, 2018-2029
6.3.2 US Cell and Gene Therapy CDMO Market Size, 2018-2029
6.3.3 Canada Cell and Gene Therapy CDMO Market Size, 2018-2029
6.3.4 Mexico Cell and Gene Therapy CDMO Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Cell and Gene Therapy CDMO Revenue, 2018-2029
6.4.2 Germany Cell and Gene Therapy CDMO Market Size, 2018-2029
6.4.3 France Cell and Gene Therapy CDMO Market Size, 2018-2029
6.4.4 U.K. Cell and Gene Therapy CDMO Market Size, 2018-2029
6.4.5 Italy Cell and Gene Therapy CDMO Market Size, 2018-2029
6.4.6 Russia Cell and Gene Therapy CDMO Market Size, 2018-2029
6.4.7 Nordic Countries Cell and Gene Therapy CDMO Market Size, 2018-2029
6.4.8 Benelux Cell and Gene Therapy CDMO Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Cell and Gene Therapy CDMO Revenue, 2018-2029
6.5.2 China Cell and Gene Therapy CDMO Market Size, 2018-2029
6.5.3 Japan Cell and Gene Therapy CDMO Market Size, 2018-2029
6.5.4 South Korea Cell and Gene Therapy CDMO Market Size, 2018-2029
6.5.5 Southeast Asia Cell and Gene Therapy CDMO Market Size, 2018-2029
6.5.6 India Cell and Gene Therapy CDMO Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Cell and Gene Therapy CDMO Revenue, 2018-2029
6.6.2 Brazil Cell and Gene Therapy CDMO Market Size, 2018-2029
6.6.3 Argentina Cell and Gene Therapy CDMO Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Cell and Gene Therapy CDMO Revenue, 2018-2029
6.7.2 Turkey Cell and Gene Therapy CDMO Market Size, 2018-2029
6.7.3 Israel Cell and Gene Therapy CDMO Market Size, 2018-2029
6.7.4 Saudi Arabia Cell and Gene Therapy CDMO Market Size, 2018-2029
6.7.5 UAE Cell and Gene Therapy CDMO Market Size, 2018-2029
7 Cell and Gene Therapy CDMO Companies Profiles
7.1 Lonza
7.1.1 Lonza Company Summary
7.1.2 Lonza Business Overview
7.1.3 Lonza Cell and Gene Therapy CDMO Major Product Offerings
7.1.4 Lonza Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.1.5 Lonza Key News & Latest Developments
7.2 Charles River Laboratories
7.2.1 Charles River Laboratories Company Summary
7.2.2 Charles River Laboratories Business Overview
7.2.3 Charles River Laboratories Cell and Gene Therapy CDMO Major Product Offerings
7.2.4 Charles River Laboratories Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.2.5 Charles River Laboratories Key News & Latest Developments
7.3 Cytiva
7.3.1 Cytiva Company Summary
7.3.2 Cytiva Business Overview
7.3.3 Cytiva Cell and Gene Therapy CDMO Major Product Offerings
7.3.4 Cytiva Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.3.5 Cytiva Key News & Latest Developments
7.4 Catalent Biologics
7.4.1 Catalent Biologics Company Summary
7.4.2 Catalent Biologics Business Overview
7.4.3 Catalent Biologics Cell and Gene Therapy CDMO Major Product Offerings
7.4.4 Catalent Biologics Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.4.5 Catalent Biologics Key News & Latest Developments
7.5 FUJIFILM Diosynth Biotechnologies
7.5.1 FUJIFILM Diosynth Biotechnologies Company Summary
7.5.2 FUJIFILM Diosynth Biotechnologies Business Overview
7.5.3 FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy CDMO Major Product Offerings
7.5.4 FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.5.5 FUJIFILM Diosynth Biotechnologies Key News & Latest Developments
7.6 BioCentriq
7.6.1 BioCentriq Company Summary
7.6.2 BioCentriq Business Overview
7.6.3 BioCentriq Cell and Gene Therapy CDMO Major Product Offerings
7.6.4 BioCentriq Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.6.5 BioCentriq Key News & Latest Developments
7.7 RoslinCT
7.7.1 RoslinCT Company Summary
7.7.2 RoslinCT Business Overview
7.7.3 RoslinCT Cell and Gene Therapy CDMO Major Product Offerings
7.7.4 RoslinCT Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.7.5 RoslinCT Key News & Latest Developments
7.8 Thermo Scientific
7.8.1 Thermo Scientific Company Summary
7.8.2 Thermo Scientific Business Overview
7.8.3 Thermo Scientific Cell and Gene Therapy CDMO Major Product Offerings
7.8.4 Thermo Scientific Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.8.5 Thermo Scientific Key News & Latest Developments
7.9 Mesoblast
7.9.1 Mesoblast Company Summary
7.9.2 Mesoblast Business Overview
7.9.3 Mesoblast Cell and Gene Therapy CDMO Major Product Offerings
7.9.4 Mesoblast Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.9.5 Mesoblast Key News & Latest Developments
7.10 Cellularity
7.10.1 Cellularity Company Summary
7.10.2 Cellularity Business Overview
7.10.3 Cellularity Cell and Gene Therapy CDMO Major Product Offerings
7.10.4 Cellularity Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.10.5 Cellularity Key News & Latest Developments
7.11 Bluebird Bio
7.11.1 Bluebird Bio Company Summary
7.11.2 Bluebird Bio Business Overview
7.11.3 Bluebird Bio Cell and Gene Therapy CDMO Major Product Offerings
7.11.4 Bluebird Bio Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.11.5 Bluebird Bio Key News & Latest Developments
7.12 Editas Medicine
7.12.1 Editas Medicine Company Summary
7.12.2 Editas Medicine Business Overview
7.12.3 Editas Medicine Cell and Gene Therapy CDMO Major Product Offerings
7.12.4 Editas Medicine Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.12.5 Editas Medicine Key News & Latest Developments
7.13 Andelyn Biosciences
7.13.1 Andelyn Biosciences Company Summary
7.13.2 Andelyn Biosciences Business Overview
7.13.3 Andelyn Biosciences Cell and Gene Therapy CDMO Major Product Offerings
7.13.4 Andelyn Biosciences Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.13.5 Andelyn Biosciences Key News & Latest Developments
7.14 Wuxi Advanced Therapies
7.14.1 Wuxi Advanced Therapies Company Summary
7.14.2 Wuxi Advanced Therapies Business Overview
7.14.3 Wuxi Advanced Therapies Cell and Gene Therapy CDMO Major Product Offerings
7.14.4 Wuxi Advanced Therapies Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.14.5 Wuxi Advanced Therapies Key News & Latest Developments
7.15 AGC Biologics
7.15.1 AGC Biologics Company Summary
7.15.2 AGC Biologics Business Overview
7.15.3 AGC Biologics Cell and Gene Therapy CDMO Major Product Offerings
7.15.4 AGC Biologics Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.15.5 AGC Biologics Key News & Latest Developments
7.16 Pfizer CentreOne
7.16.1 Pfizer CentreOne Company Summary
7.16.2 Pfizer CentreOne Business Overview
7.16.3 Pfizer CentreOne Cell and Gene Therapy CDMO Major Product Offerings
7.16.4 Pfizer CentreOne Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.16.5 Pfizer CentreOne Key News & Latest Developments
7.17 Almac Group
7.17.1 Almac Group Company Summary
7.17.2 Almac Group Business Overview
7.17.3 Almac Group Cell and Gene Therapy CDMO Major Product Offerings
7.17.4 Almac Group Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.17.5 Almac Group Key News & Latest Developments
7.18 PCI Pharma Services
7.18.1 PCI Pharma Services Company Summary
7.18.2 PCI Pharma Services Business Overview
7.18.3 PCI Pharma Services Cell and Gene Therapy CDMO Major Product Offerings
7.18.4 PCI Pharma Services Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.18.5 PCI Pharma Services Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer